Shingrix in Immunosuppression — RACP Adult Medicine MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Use the recombinant (non-live) zoster vaccine (Shingrix) instead
Live vaccines are contraindicated in patients on biologic immunosuppressants. The recombinant zoster vaccine (Shingrix – a non-live adjuvanted vaccine) is safe and effective in immunosuppressed patients and is recommended for adults ≥50 years or those ≥18 years on immunosuppression. It provides >90% protection against herpes zoster. Shingrix is funded under the NIP for eligible Australians ≥50 years and immunocompromised individuals ≥18 years.
Reference: ATAGI – 2024 – Australian Immunisation Handbook; AMH – 2025 – Vaccines